2005; 58(10):982-990 283. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available from: http://tech.cochrane.org/Revman 284. Richardson DM, Bain KT, Diamond JJ, Novielli KD, Lee SP, Goldfarb NI. Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly medicare heart Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 failure population: a retrospective, survey-weighted, cohort analysis. Drugs and Aging. 2010; 285. Riegel B, Carlson B, Glaser D, Romero T. Randomized controlled trial of telephone case management in Hispanics of Mexican origin with heart failure. Journal of Cardiac Failure. 286. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. Effect of a standardized nurse case- management telephone intervention on resource use in patients with chronic heart failure. Archives of Internal Medicine. 2002; 162(6):705-12 287. Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. 288. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circulation: Heart Failure. 289. Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. European Heart Journal. 290. 